1 | pulmonary hypertension at the | | | | | | | 2 | 0.66% |
2 | new lung deposition modeling | | | | | | | 2 | 0.66% |
3 | aerami therapeutics to present | | | | | | | 2 | 0.66% |
4 | aerami therapeutics holdings inc | | | | | | | 2 | 0.66% |
5 | hypertension at the american | | | | | | | 2 | 0.66% |
6 | lung deposition modeling data | | | | | | | 2 | 0.66% |
7 | deposition modeling data for | | | | | | | 2 | 0.66% |
8 | for inhalation that is | | | | | | | 1 | 0.33% |
9 | to main content skip | | | | | | | 1 | 0.33% |
10 | that is administered by | | | | | | | 1 | 0.33% |
11 | is administered by a | | | | | | | 1 | 0.33% |
12 | breathactivated highperformance handheld smart | | | | | | | 1 | 0.33% |
13 | highperformance handheld smart nebulizer | | | | | | | 1 | 0.33% |
14 | handheld smart nebulizer that | | | | | | | 1 | 0.33% |
15 | controls flow rate and | | | | | | | 1 | 0.33% |
16 | flow rate and provides | | | | | | | 1 | 0.33% |
17 | rate and provides realtime | | | | | | | 1 | 0.33% |
18 | and provides realtime feedback | | | | | | | 1 | 0.33% |
19 | provides realtime feedback to | | | | | | | 1 | 0.33% |
20 | imatinib for inhalation that | | | | | | | 1 | 0.33% |
21 | feedback to help optimize | | | | | | | 1 | 0.33% |
22 | aerami therapeutics presents new | | | | | | | 1 | 0.33% |
23 | therapeutics presents new lung | | | | | | | 1 | 0.33% |
24 | presents new lung deposition | | | | | | | 1 | 0.33% |
25 | in pulmonary hypertension at | | | | | | | 1 | 0.33% |
26 | aer901 in pulmonary hypertension | | | | | | | 1 | 0.33% |
27 | realtime feedback to help | | | | | | | 1 | 0.33% |
28 | skip to main content | | | | | | | 1 | 0.33% |
29 | of imatinib for inhalation | | | | | | | 1 | 0.33% |
30 | to efficiently deliver imatinib | | | | | | | 1 | 0.33% |
31 | an innovative approach to | | | | | | | 1 | 0.33% |
32 | innovative approach to pulmonary | | | | | | | 1 | 0.33% |
33 | approach to pulmonary hypertension | | | | | | | 1 | 0.33% |
34 | aer901 is a drugdevice | | | | | | | 1 | 0.33% |
35 | is a drugdevice combination | | | | | | | 1 | 0.33% |
36 | a drugdevice combination product | | | | | | | 1 | 0.33% |
37 | drugdevice combination product candidate | | | | | | | 1 | 0.33% |
38 | combination product candidate that | | | | | | | 1 | 0.33% |
39 | product candidate that is | | | | | | | 1 | 0.33% |
40 | designed to efficiently deliver | | | | | | | 1 | 0.33% |